Blog
Using CANTAB to develop AI-based tools for the early detection of dementia
To mark World Alzheimer's Day, we hear from Christoffer Hatlestad-Hall and his team at Oslo University Hospital, who explain how CANTABTM is an instrumental part of their study using AI and machine learning to identify the earliest signs of Alzheimer's and dementia in people with mild cognitive impairment.
Join us at AAIC 2022
We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.
Using CANTAB to identify undiagnosed dementia cases using a web-based pre-screening tool in the MOPE
We recently caught up with Dr. Mercè Boada, the project coordinator of MOPEAD, and Medical Director of Ace Alzheimer Center Barcelona to discuss her recent publication supporting the use of CANTAB for the early detection of undiagnosed people with cognitive impairment.
New study uses CANTAB to differentiate typical and pathological ageing
Find out more about how María Campos Magdaleno, PhD of Universidade de Santiago de Compostela is using CANTAB to investigate cognitive changes in typical and pathological ageing.
Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, c
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1
Interim Analysis of Online Screening as a Recruitment Strategy for MOPEAD
At AAIC 2019 we presented an interim analysis of online screening as a recruitment strategy for the MOPEAD initiative. The initial findings are positive, with high levels of engagement from older adults, as well as sensitivity to impairment.
Large-Scale Remote Assessment of Verbal Cognitive Function Using Automatic Speech Recognition
At AAIC 2019, we shared how to administer and score verbal neuropsychological assessments on participants own devices in a way that is acceptable, feasible and reliable.
CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Using CANTAB to investigate age-related cognitive changes associated with dementia in Down syndrome
PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.
Neural Network classification of longitudinal cognitive data for prediction of individual-level chan
For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018.
CANTAB Mobile: experience of use of a digital memory assessment tool in UK primary care
Cambridge Cognition presented new data at AAIC 2018 that demonstrates a demand from patients for the objective assessment of memory function, and describes how CANTAB testing can triage these memory complaints in clinic.
CANTAB technology selected for world’s largest dementia study
We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
CANTAB Recruit software to be used in two major Phase III drug trials
We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.
What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
The CANTAB Paired Associates Learning task as a pre-screening tool for clinical trials
Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.
Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Alzheimer's research technology showcase - AAIC 2017
Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
Paired Associates Learning: Adding Sensitivity By Measuring Reaction Times
Computerised testing brings an unprecedented ability to capture more detailed information about patient responses. This could provide novel insights into cognitive processes, and greater discriminatory power in predicting cognitive deficits and decline in Alzheimer's and other diseases.
Feasibility of automated voice based cognitive assessment on a consumer voice platform
Exploring the use of automated voice based cognitive assessments on consumer voice platforms.
Cognition and Alzheimer's Technology at AAIC 2017
Cambridge Cognition is attending the Alzheimer's Association International Conference in London.
Evaluating familiarity deficits related to conversion of MCI to Alzheimer’s disease
The early identification of individuals at risk of Alzheimer's Disease (AD) is of primary importance for the development of new effective interventions to stop the progression of the disease before the onset of severe neurodegeneration and clinical manifestations.
